PROGYNY INC (PGNY)
US74340E1038 - Common Stock
PGNY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 109 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making PGNY a very profitable company, without any liquidiy or solvency issues. PGNY is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make PGNY suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
PGNY had positive earnings in the past year.
In the past year PGNY had a positive cash flow from operations.
Of the past 5 years PGNY 4 years were profitable.
PGNY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
PGNY has a better Return On Assets (8.68%) than 93.52% of its industry peers.
The Return On Equity of PGNY (13.17%) is better than 82.41% of its industry peers.
The Return On Invested Capital of PGNY (12.72%) is better than 91.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PGNY is in line with the industry average of 8.15%.
The last Return On Invested Capital (12.72%) for PGNY is above the 3 year average (8.61%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROIC | 12.73% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
1.3 Margins
PGNY has a better Profit Margin (5.03%) than 83.33% of its industry peers.
PGNY's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 5.75%, PGNY is doing good in the industry, outperforming 67.59% of the companies in the same industry.
PGNY's Operating Margin has improved in the last couple of years.
PGNY has a Gross Margin (21.68%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of PGNY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% |
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
2. Health
2.1 Basic Checks
PGNY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
PGNY has more shares outstanding than it did 1 year ago.
PGNY has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PGNY has an Altman-Z score of 6.21. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
PGNY has a Altman-Z score of 6.21. This is amongst the best in the industry. PGNY outperforms 90.74% of its industry peers.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.21 |
ROIC/WACC1.38
WACC9.21%
2.3 Liquidity
PGNY has a Current Ratio of 2.62. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY's Current ratio of 2.62 is amongst the best of the industry. PGNY outperforms 84.26% of its industry peers.
PGNY has a Quick Ratio of 2.62. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY's Quick ratio of 2.62 is amongst the best of the industry. PGNY outperforms 84.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
PGNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.54%, which is quite good.
The Earnings Per Share has been growing by 97.89% on average over the past years. This is a very strong growth
The Revenue has grown by 10.24% in the past year. This is quite good.
PGNY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.52% yearly.
EPS 1Y (TTM)11.54%
EPS 3Y97.89%
EPS 5YN/A
EPS Q2Q%-31.25%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Sales Q2Q%2.04%
3.2 Future
PGNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.33% yearly.
The Revenue is expected to grow by 8.60% on average over the next years. This is quite good.
EPS Next Y-9.78%
EPS Next 2Y-0.17%
EPS Next 3Y13.59%
EPS Next 5Y31.33%
Revenue Next Year4.76%
Revenue Next 2Y2.92%
Revenue Next 3Y5.71%
Revenue Next 5Y8.6%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 24.72 indicates a rather expensive valuation of PGNY.
65.74% of the companies in the same industry are more expensive than PGNY, based on the Price/Earnings ratio.
PGNY's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.73.
Based on the Price/Forward Earnings ratio of 23.21, the valuation of PGNY can be described as rather expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as PGNY.
PGNY is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.72 | ||
| Fwd PE | 23.21 |
4.2 Price Multiples
PGNY's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. PGNY is cheaper than 64.81% of the companies in the same industry.
93.52% of the companies in the same industry are more expensive than PGNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.61 | ||
| EV/EBITDA | 12.29 |
4.3 Compensation for Growth
The decent profitability rating of PGNY may justify a higher PE ratio.
PGNY's earnings are expected to grow with 13.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.17%
EPS Next 3Y13.59%
5. Dividend
5.1 Amount
PGNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROGYNY INC
NASDAQ:PGNY (12/20/2024, 8:00:00 PM)
After market: 14.33 -0.01 (-0.07%)14.34
+0.15 (+1.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.26%
Inst Owner Change-7.72%
Ins Owners6.57%
Ins Owner Change-0.57%
Market Cap1.22B
Analysts77.65
Price Target19 (32.5%)
Short Float %15.78%
Short Ratio6.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.36%
Min EPS beat(2)-19.12%
Max EPS beat(2)-1.61%
EPS beat(4)2
Avg EPS beat(4)6.11%
Min EPS beat(4)-19.12%
Max EPS beat(4)26.05%
EPS beat(8)6
Avg EPS beat(8)48.62%
EPS beat(12)10
Avg EPS beat(12)123.05%
EPS beat(16)13
Avg EPS beat(16)111.27%
Revenue beat(2)0
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-5.35%
Max Revenue beat(2)-2.39%
Revenue beat(4)0
Avg Revenue beat(4)-4.25%
Min Revenue beat(4)-5.82%
Max Revenue beat(4)-2.39%
Revenue beat(8)3
Avg Revenue beat(8)-1.11%
Revenue beat(12)5
Avg Revenue beat(12)-1.25%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)-3.25%
PT rev (3m)-38.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.3%
EPS NY rev (1m)-22.76%
EPS NY rev (3m)-8.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.64%
Revenue NY rev (1m)-2.34%
Revenue NY rev (3m)-2.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.72 | ||
| Fwd PE | 23.21 | ||
| P/S | 1.07 | ||
| P/FCF | 7.61 | ||
| P/OCF | 7.42 | ||
| P/B | 2.81 | ||
| P/tB | 2.92 | ||
| EV/EBITDA | 12.29 |
EPS(TTM)0.58
EY4.04%
EPS(NY)0.62
Fwd EY4.31%
FCF(TTM)1.88
FCFY13.14%
OCF(TTM)1.93
OCFY13.48%
SpS13.37
BVpS5.11
TBVpS4.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROCE | 14.5% | ||
| ROIC | 12.73% | ||
| ROICexc | 26.63% | ||
| ROICexgc | 28.94% | ||
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% | ||
| FCFM | 14.09% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
ROICexc(3y)19.38%
ROICexc(5y)20.33%
ROICexgc(3y)20.85%
ROICexgc(5y)26.41%
ROCE(3y)9.81%
ROCE(5y)9.05%
ROICexcg growth 3Y24.58%
ROICexcg growth 5YN/A
ROICexc growth 3Y31.27%
ROICexc growth 5YN/A
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
F-Score7
Asset Turnover1.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 139.02% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 240.38% | ||
| Profit Quality | 280.06% | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 6.21 |
F-Score7
WACC9.21%
ROIC/WACC1.38
Cap/Depr(3y)175.37%
Cap/Depr(5y)143.9%
Cap/Sales(3y)0.39%
Cap/Sales(5y)0.55%
Profit Quality(3y)196.21%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.54%
EPS 3Y97.89%
EPS 5YN/A
EPS Q2Q%-31.25%
EPS Next Y-9.78%
EPS Next 2Y-0.17%
EPS Next 3Y13.59%
EPS Next 5Y31.33%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Sales Q2Q%2.04%
Revenue Next Year4.76%
Revenue Next 2Y2.92%
Revenue Next 3Y5.71%
Revenue Next 5Y8.6%
EBIT growth 1Y26.63%
EBIT growth 3Y89.07%
EBIT growth 5YN/A
EBIT Next Year128%
EBIT Next 3Y39.34%
EBIT Next 5Y26.82%
FCF growth 1Y363.59%
FCF growth 3Y73.98%
FCF growth 5Y155.82%
OCF growth 1Y336.49%
OCF growth 3Y73.42%
OCF growth 5Y142.1%